Johnson & Johnson said it would take a $13.6 billion charge related to the new U.S. tax law and plans to bring back billions of dollars from overseas immediately.
Biotech deal activity exploded with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion to add new products to their medicine cabinets.
Nuvo Pharmaceuticals acquired the U.S. rights to Resultz head lice treatment from Piedmont Pharmaceuticals.
Teva Pharmaceutical Industries’ board of directors agreed to take a 50 percent pay cut.
The Trump administration’s tax overhaul should accelerate major acquisitions by drugmakers in 2018, say senior execs from some of the largest manufacturers.
Novo Nordisk A/S has twice made a bid to acquire Ablynx NV, and twice been rejected.
Celgene Corporation will acquire Impact Biomedicines – which is developing fedratinib for myelofibrosis and polycythemia vera – for $1.1 billion upfront.
Takeda CEO Christophe Weber is sticking to his game plan of actively hunting deals that will expand its global presence and create a stronger international profile.
Shares of Belgium-based TiGenix NV shot up after Japan’s Takeda Pharmaceutical opted to acquire the company for $630 million.
Pernix Therapeutics is undergoing a reorganization that includes the termination of a number of sales representatives.